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ABSTRACT
Pioglitazone, a thiazolidinedione, improves
insulin sensitivity and thus reduces blood
glucose. Clinical trials have suggested
potential cardiovascular outcome benefits in
association with pioglitazone; however, safety
concerns are mounting, with recent data
suggesting a link between pioglitazone and an
increased risk of bladder cancer. There is thus a
growing focus on the risk–benefit profile of this
agent and hence its potential role in the blood
glucose-lowering treatment algorithm for
people with type 2 diabetes. There are clear
potential outcome benefits associated with
pioglitazone. In this review, the authors focus
on putting the true risk–benefit profile of
pioglitazone into context based on critical
appraisal of the currently available evidence.
Keywords: Bladder cancer; Pioglitazone;
Thiazolidenidione; Type 2 diabetes
INTRODUCTION
Pioglitazone is the only thiazolidinedione (TZD)
that is currently available in Europe. During the
last few years, the focus has been on the side-
effect profile of this group of medications. In
2007, following a meta-analysis by Nissen et al.
[1] on the cardiovascular safety of rosiglitazone,
it was shown that rosiglitazone was associated
with cardiovascular risk in terms of increased
risk of myocardial infarction (MI). Further to
this, the US Food and Drug Administration
(FDA) have given strict criteria for new
prescriptions and additional warning labeling
for rosiglitazone. The European Medicine
Agency (EMA) has withdrawn the marketing
authorization for rosiglitazone. Of late,
concerns have also been raised regarding a
possible link between pioglitazone use and
bladder cancer [2–4]. Here, the authors review
the risk–benefit profile of pioglitazone, with a
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particular focus on the putative link between
pioglitazone and bladder cancer.
METHODS
English language articles were included in the
literature search, including the key terms
‘‘pioglitazone,’’ ‘‘bladder cancer,’’ and ‘‘type 2
diabetes.’’ The literature search included clinical




Following concerns regarding the
cardiovascular safety of rosiglitazone, the
effect of pioglitazone on cardiovascular
outcomes has been closely evaluated in recent
years. Even though they belong to the same
class, unlike rosiglitazone, pioglitazone has a
favorable cardiovascular outcome.
A meta-analysis of 19 trials comparing
pioglitazone with placebo or active comparator
in 16,390 patients with diabetes has shown that
pioglitazone was associated with a significantly
lower risk of death, MI, or stroke [5]. Death, MI,
or stroke occurred in 375 out of 8,554 patients
(4.4%) on pioglitazone therapy as compared to
450 of 7,836 patients (5.7%) receiving
controlled therapy [hazard ratio (HR) = 0.82;
95% CI, 0.72–0.94; P = 0.005].
In the PROspective pioglitAzone Clinical Trial
In macroVascular Events (PROactive) study, the
primary composite endpoint (mortality,
nonfatal MI, silent MI, stroke, acute coronary
syndrome, endovascular or surgical intervention
on the coronary or leg arteries, major leg
amputation) analysis failed to show a beneficial
effect for pioglitazone [6]. The HR for primary
composite endpoint was 0.904 in favor of
pioglitazone (95% CI, 0.80–1.08; P = 0.095).
For the primary endpoint, the 3-year placebo
event rate was 23.5% and the pioglitazone event
rate was 21% (relative risk reduction of 10%); the
number needed to treat (NNT) to prevent one
cardiovascular event was 120 per year [6–9]. The
prespecified main secondary endpoint was
death, MI, and stroke. Analysis of the main
secondary endpoint has shown a significant
benefit for pioglitazone (HR = 0.84; 95% CI,
0.722–0.981; P = 0.027). For the main secondary
endpoint (placebo event rate 13.6% and
pioglitazone event rate 11.6%), NNT was 143
per year. Furthermore, the statistical significance
is lost only when revascularization procedures
are included within the primary composite
endpoint. In other words, when commonly
used cardiovascular outcomes (death, MI, or
stroke) are evaluated, the statistically
significant beneficial effect of pioglitazone is
revealed. A further subgroup analysis of the
PROactive study (PROactive 05) looked at the
effect of pioglitazone on recurrent MI in 2,445
patients with diabetes and previous MI [8]. This
showed that patients treated with pioglitazone
had a statistically significant beneficial effect on
the prespecified endpoint of fatal and nonfatal
MI (P = 0.045; 28% relative risk reduction)
which translates into an estimated NNT of
approximately 149 per year and acute coronary
syndrome (P = 0.035; 37% risk reduction)
compared with those treated with placebo.
Two other studies which looked at the effect
of pioglitazone on the progression of
atherosclerosis have also shown a favorable
outcome. Carotid artery intima media
thickness (CIMT) is a surrogate marker for
cardiovascular disease. A study comparing the
effect of pioglitazone versus glimepiride on
changes in CIMT in type 2 diabetes patients
has shown that over an 18-month period,
pioglitazone slowed progression of CIMT
compared with glimepiride [10]. In the
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Prospective Evaluation of a RIsk Score for
postoperative pulmonary COmPlications in
Europe (PERISCOPE) study, coronary
intravascular ultrasonography (IVUS) was used
to assess the change in percent atheroma
volume in patients with type 2 diabetes and
coronary artery disease, and the study
compared pioglitazone with glimepiride [10].
In total, 360 patients completed the final IVUS
assessment at 18 months, which showed that
pioglitazone-treated patients had a significantly
lower rate of progression of coronary
atherosclerosis, compared with patients treated
with glimepiride. Both these studies have used
surrogate markers to assess the effect of
pioglitazone on atherosclerosis, which has
shown that the pioglitazone slows the
progression of atherosclerosis compared to an
active comparator (sulfonylurea).
In summary, pioglitazone appears to be
associated with potential cardiovascular
outcome benefits (Table 1) [5–10].
HEART FAILURE
Heart failure is the most commonly recognized
side effect of pioglitazone. TZDs cause fluid
retention and peripheral edema, predisposing
the susceptible patients to heart failure. No
detrimental effect on left ventricular function
has been shown with TZDs. The pioglitazone
meta-analysis revealed that serious heart failure
was reported in 200 (2.3%) of pioglitazone-treated
patients, compared with 139 (1.8%) of the control
patients (HR = 1.41; 95% CI, 1.14–1.76;
P = 0.002), but the composite endpoint of death
and serious heart failure was not statistically
different in the two groups [5]. The data from
the PROactive study specifically looking at
pioglitazone use and heart failure (PROactive 08)
also showed a significant increase in heart failure
in pioglitazone-treated patients, but subsequent
analysis of patients who developed serious heart
failure has shown that the all-cause mortality was
proportionately lower with the pioglitazone
group (40/149; 26.8%) compared with the
placebo group (37/108; 34.3%) (P = 0.1338) [7].
The composite endpoint of death, nonfatal MI, or
stroke was much less in pioglitazone patients with
serious heart failure (34.9%) compared with
placebo (47.2%), which was statistically
significant (P = 0.025).
PIOGLITAZONE AND BLADDER
CANCER
Experimental studies have reported that
peroxisome proliferator-activated receptor
(PPAR) agonists like pioglitazone and dual
PPAR gamma/PPAR alpha agonists like
muraglitazar induce urothelial bladder tumors
[12]. Initial studies suggested that this is a rat-
specific phenomenon [11]. Two mechanisms
were postulated for this phenomenon.
Urothilium has plenty of PPAR gamma
receptors, and direct interaction of the agonist
with the receptors ultimately leading to
induction of cancer was one possible
mechanism suggested. But it has been shown
that even though the PPAR gamma expression
was at similar levels in rat and mouse
urothelium, the TZD produced bladder tumors
only in the rat and not in the mouse. In-vitro
studies using human urothelial cell lines have
shown that PPAR gamma agonists inhibit cell
proliferation, hence a direct carcinogenic effect
to the urothelium by the PPAR gamma agonist
is less likely [11]. Also, as PPAR agonists are
highly lipophilic, only a small percentage of
administered drugs get excreted in the urine,
reducing the exposure of the drug to the
urothelium. The second postulated mechanism
involves alteration to the urinary composition
leading to cytotoxicity, necrosis, and urothelial
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proliferation. Studies have shown that both
PPAR gamma agonists and PPAR gamma/PPAR
alpha agonists alter urinary composition,
resulting in calcium containing urinary solids
to varying degrees [11]. This is associated with
increased urothelial injury, necrosis, and
regenerative proliferation. The amount of
urinary solids detected in rats treated with
pioglitazone was less than that observed for
rats treated with muraglitazar [11]. As expected,
muraglitazar induced a significantly higher
incidence of bladder tumors than the small
number induced by pioglitazone. The evidence
from experimental studies supports the
hypothesis that potential cytotoxicity may be
related to urinary solids, namely calcium
containing crystals and calculi [11].
An interim report of a longitudinal cohort
study conducted between 1997 and 2002, that
assessed the risk of bladder cancer among
diabetic patients treated with pioglitazone
(including 193,099 patients in the Kaiser
Permanente Northern California Diabetes
Registry, [40 years of age) showed that after
adjusting for age, sex, tobacco use, and use of
other categories of diabetes medications, there
was no significant increase in the risk of bladder
cancer in patients ever exposed to pioglitazone,
compared with patients never exposed to
pioglitazone (HR = 1.2; 95% CI, 0.9–1.5), with
similar results in men and women [12].
However, the risk of bladder cancer rose with
increasing duration of pioglitazone use.
Compared to never being used, pioglitazone
treatment for more than 24 months was
associated with a 40% increase in relative risk
of developing bladder cancer (HR = 1.4; 95% CI,
0.9–2.1). Based on these data, the FDA calculated
that duration of therapy longer than 12 months
was associated with 27.5 excess cases of bladder
cancer per 100,000 person-years follow-up,
compared with no use of pioglitazone [13].
More recently, Piccinni et al. [14] have
reported further evidence for the association of
pioglitazone use and bladder cancer after
analyzing the data from the FDA’s drug
adverse event reporting system. They retrieved
data regarding drug adverse events concerning
antidiabetic medications between 2004 and
2009. The association between antidiabetic
drugs and bladder cancer was analyzed by
case/non-case methodology using reporting
odds ratio (ROR) as a measure of
disproportionality. Overall, 93 reports of
bladder cancer were retrieved, corresponding
to 138 drug reaction pairs (obtained by splitting
co-medications and multiple reactions reported
for each case). The ROR for bladder cancer was
4.3 for pioglitazone (95% CI, 2.82–6.52;
P \ 0.001). The ROR for gliclazide was 3.56
(95% CI, 1.42–8.39) and for acarbose it was 5.12
(95% CI, 1.0–14.33). With the number of
bladder cancer cases reported with gliclazide
and acarbose being small, it is too susceptible to
reporting biases, and hence not clinically
relevant. But this report concluded that there
was a definite signal for bladder cancer
associated with pioglitazone use [11].
A retrospective cohort study using the data
from the French National Health Insurance
System also showed an increased risk of bladder
cancer with pioglitazone use [12]. This study was
from a cohort of 1,491,060 diabetes patients on
drug therapy, aged 40–79, followed-up for up to
4 years (2006–2009). Of these, 155,535 patients
were pioglitazone treated. The results showed
that after adjusting for age, sex, and use of other
antidiabetic medications, there was a statistically
significant increase in the risk of bladder cancer
in patients exposed to pioglitazone, compared
with patients exposed to other antidiabetic
agents (HR = 1.22; 95% CI, 1.03–1.43). The
results also showed a dose effect related to
cumulative dose [28,000 mg (HR = 1.75; 95%
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CI, 1.22–2.5) and for exposure longer than 1 year
(HR = 1.34; 95% CI, 1.02–1.75). A significant
increase in risk was observed in males
(HR = 1.28; 95% CI, 1.09–1.51) [13].
FRACTURE RISK
TZDs affect the bone homeostasis adversely.
Mesenchymal stem cells in the bone act as the
common progenitor of both adipocytes and
osteoblasts [15]. TZD alters the maturation of
mesenchymal stem cells. This affects the bone
density and osteoblast functioning, which leads
to reduced osteoblast activity, shifting the
balance of bone homeostasis to favor bone loss.
Clinical studies have shown an increased risk
of fractures, especially in females. In the
PERISCOPE study, fractures occurred in 3% of
patients treated with pioglitazone, compared
with none in the glimepiride group [7].
An analysis of the clinical trial database of
the pioglitazone manufacturer with a special
focus on fractures has shown an excess risk in
female patients [16]. There was no increased risk
of fracture identified in men. The majority of
fractures observed in female patients who
received pioglitazone were in the distal upper
limb (forearm, hand, and wrist) or distal lower
limb (foot, ankle, fibula, and tibia). The
calculated fracture incidence was 1.9 per 100
patient-years in the pioglitazone-treated group
and 1.1 fractures per 100 patient-years in the
comparator treated group, resulting in an excess
fracture risk of 0.8 fractures per 100 patient-
years of pioglitazone use [16].
REGULATORY CONSIDERATIONS
FOR PIOGLITAZONE
Following the retrospective study conducted by
the National Health Insurance Agency, the
French agency for drug regulations (AFSSAPS)
have suspended the use of pioglitazone in
France since June 2011 [17].
The FDA safety communication in June 2011
announced that the use of pioglitazone for more
than 1 year may be associated with an increased
risk of bladder cancer [13]. It recommended not
to use pioglitazone in patients with active
bladder cancer, and to evaluate risks and
benefits before initiating pioglitazone [3]. The
FDA encourages physicians to counsel patients
regarding the symptoms of bladder cancer [3].
In July 2011, the EMA concluded that the
evidence from different sources showed a small
increased risk of bladder cancer with
pioglitazone, in particular in patients treated
for the longest durations and with the highest
cumulative doses [2]. The EMA advised the
clinicians not to use pioglitazone in patients
with a past or current history of bladder cancer
or in patients with uninvestigated macroscopic
hematuria. Various risk factors for bladder
cancer (elderly people, smoking, previous
exposure to occupational risk factors, or drugs
related to a risk of bladder cancer) should be
assessed before initiating pioglitazone. The
balance of risk and benefits should be assessed
before as well as during treatment with
pioglitazone, to ensure that only patients who
are deriving sufficient benefit continue to take it.
CONCLUSION
Pioglitazone remains a useful blood glucose-
lowering therapy and may produce significant
clinical benefits for some patients, particularly
from the perspective of potential cardiovascular
outcomes. It would therefore be inappropriate
to recommend discontinuation of pioglitazone
use for all patients. A number of safety concerns
have been identified with pioglitazone,
including an increased risk of cardiac failure,
bone fracture, and a small but definite increase
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in the risk of bladder cancer. Thus, when
considering the use of pioglitazone, an
individualized patient risk–benefit evaluation
is essential with the use of pioglitazone being
inappropriate in people considered at risk of
bone fracture, cardiac failure, or bladder cancer.
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